Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are emerging problems in several countries. These infections require long and expensive treatment regimens. Recently, 2 new drugs, bedaquiline and delamanid, have been approved in several countries for use in adults with severe, difficult-to-treat MDR-TB, and it has been suggested that they could also be administered to children with MDR-TB and limited treatment options. However, no study has been completed on their efficacy.
Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis : a case report and review of the literature / S. Esposito, S. Bosis, M. Tadolini, S. Bianchini, G.B. Migliori, N. Principi. - In: MEDICINE. - ISSN 0025-7974. - 95:46(2016 Nov), pp. e5347.1-e5347.4.
|Titolo:||Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis : a case report and review of the literature|
ESPOSITO, SUSANNA (Primo)
BOSIS, SAMANTHA (Secondo)
PRINCIPI, NICOLA (Ultimo)
|Parole Chiave:||Antitubercular Agents; Child; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Italy; Male; Nitroimidazoles; Oxazoles|
|Settore Scientifico Disciplinare:||Settore MED/38 - Pediatria Generale e Specialistica|
|Data di pubblicazione:||nov-2016|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1097/MD.0000000000005347|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|Esposito Bosis Efficacy safety tolerability of delamanid.pdf||Publisher's version/PDF||Open Access Visualizza/Apri|